SEC Tracker
Get the app

Opus Genetics IRD

Opus Genetics reported a $46.5 million net loss for Q3 2026.

Opus Genetics (IRD) filed a 10-Q with the SEC on Nov 10, 2026, 4:05 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $1.14 million for the three months ended Sep 30, 2026
  2. Net loss: $46.5 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $88.97 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Opus Genetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$1.14M$755K+51%
Operating income and margin−$19.25M · -1692.8%−$16.48M · -2182.8%−17%, margin +490 pts
Net income−$46.5M−$8.1M−474%
Operating cash flow−$14.04M−$11.95M−18%
Cash$88.97M$88.81M+0.2%

Data on this page was fetched . The filing on SEC.gov is the record.